Restricted accessResearch articleFirst published online 2020-05
The Expression,Clinicopathologic Characteristics,and Prognostic Value of Androgen Receptor in Breast Cancer: A Bioinformatics Analysis Using Public Databases
The role of androgen receptor (AR) in breast cancer has been unveiled in succession for the past few years. In this study, we conducted a comprehensive analysis based on four online public databases of data from many previous studies. We found that the expression of AR is significantly related to age, histological grade, and subtype but not to lymph node status. The low expression level of AR is strongly associated with poor recurrence-free survival, especially with poor distance metastasis-free survival in luminal A patients, but inverse in HER2 (human epidermal growth factor receptor-2) enriched patients. AR might be a biomarker of chemosensitivity in the basal subtype. Besides, the expression of melanophilin (MLPH) is distinctly in accordance with that of AR. AR could play diverse roles in different subtypes of breast cancer.
Get full access to this article
View all access options for this article.
References
1.
AleskandaranyM.A., AbduljabbarR., AshankytyI., ElmounaA., JerjeesD., AliS., et al. (2016). Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis. Breast Cancer Res Treat, 159, 215–227.
2.
BasileD., CinauseroM., IaconoD., PelizzariG., BonottoM., VitaleM.G., et al. (2017). Androgen receptor in estrogen receptor positive breast cancer: beyond expression. Cancer Treat Rev, 61, 15–22.
3.
BosP.D., ZhangX.H., NadalC., ShuW., GomisR.R., NguyenD.X., et al. (2009). Genes that mediate breast cancer metastasis to the brain. Nature, 459, 1005–1009.
4.
Bozovic-SpasojevicI., ZardavasD., BroheeS., AmeyeL., FumagalliD., AdesF., et al. (2017). The prognostic role of androgen receptor in patients with early-stage breast cancer: a meta-analysis of clinical and gene expression data. Clin Cancer Res, 23, 2702–2712.
5.
BrayF., FerlayJ., SoerjomataramI., SiegelR.L., TorreL.A., and JemalA. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68, 394–424.
6.
BuH., NarisuN., SchlickB., RainerJ., MankeT., SchaferG., et al. (2016). Putative prostate cancer risk SNP in an androgen receptor-binding site of the melanophilin gene illustrates enrichment of risk SNPs in androgen receptor target sites. Hum Mutat, 37, 52–64.
7.
CarelsN., SpinasseL.B., TilliT.M., and TuszynskiJ.A. (2016). Toward precision medicine of breast cancer. Theor Biol Med Model, 13, 7.
8.
CastellanoI., AlliaE., AccortanzoV., VandoneA.M., ChiusaL., ArisioR., et al. (2010). Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat, 124, 607–617.
9.
ChoiJ.E., KangS.H., LeeS.J., and BaeY.K. (2015). Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Ann Surg Oncol, 22, 82–89.
10.
CiupekA., RechoumY., GuG., GelsominoL., BeyerA.R., BruscoL., et al. (2015). Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERalpha-positive breast cancer. Breast Cancer Res Treat, 154, 225–237.
11.
FukudaM., KurodaT.S., and MikoshibaK. (2002). Slac2-a/melanophilin, the missing link between Rab27 and myosin Va: implications of a tripartite protein complex for melanosome transport. J Biol Chem, 277, 12432–12436.
12.
GerratanaL., BasileD., BuonoG., De PlacidoS., GiulianoM., MinichilloS., et al. (2018). Androgen receptor in triple negative breast cancer: a potential target for the targetless subtype. Cancer Treat Rev, 68, 102–110.
13.
Gonzalez-AnguloA.M., Stemke-HaleK., PallaS.L., CareyM., AgarwalR., Meric-BerstamF., et al. (2009). Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res, 15, 2472–2478.
14.
GyorffyB., LanczkyA., EklundA.C., DenkertC., BudcziesJ., LiQ., et al. (2010). An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat, 123, 725–731.
15.
HeinleinC.A., and ChangC. (2004). Androgen receptor in prostate cancer. Endocr Rev, 25, 276–308.
16.
HelsenC., Van den BroeckT., VoetA., PrekovicS., Van PoppelH., JoniauS., et al. (2014). Androgen receptor antagonists for prostate cancer therapy. Endocr Relat Cancer, 21, T105–T118.
17.
HickeyT.E., RobinsonJ.L., CarrollJ.S., and TilleyW.D. (2012). Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?. Mol Endocrinol, 26, 1252–1267.
18.
HilbornE., GacicJ., FornanderT., NordenskjoldB., StalO., and JanssonA. (2016). Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-alpha-negative breast cancer. Br J Cancer, 114, 248–255.
19.
JezequelP., CamponeM., GouraudW., Guerin-CharbonnelC., LeuxC., RicolleauG., et al. (2012). bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer. Breast Cancer Res Treat, 131, 765–775.
20.
JezequelP., FrenelJ.S., CampionL., Guerin-CharbonnelC., GouraudW., RicolleauG., et al. (2013). bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analyses. Database (Oxford), 2013, bas060.
21.
JiangC., WuS., JiangL., GaoZ., LiX., DuanY., et al. (2019a). Network-based approach to identify biomarkers predicting response and prognosis for HER2-negative breast cancer treatment with taxane-anthracycline neoadjuvant chemotherapy. PeerJ, 7, e7515.
22.
JiangY.Z., MaD., SuoC., ShiJ., XueM., HuX., et al. (2019b). Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell, 35, 428.e5–440.e5.
23.
KaramouzisM.V., PapavassiliouK.A., AdamopoulosC., and PapavassiliouA.G. (2016). Targeting androgen/estrogen receptors crosstalk in cancer. Trends Cancer, 2, 35–48.
24.
KimY., JaeE., and YoonM. (2015). Influence of androgen receptor expression on the survival outcomes in breast cancer: a meta-analysis. J Breast Cancer, 18, 134–142.
25.
KonoM., FujiiT., LimB., KaruturiM.S., TripathyD., and UenoN.T. (2017). Androgen receptor function and androgen receptor-targeted therapies in breast cancer: a review. JAMA Oncol, 3, 1266–1273.
26.
LehmannB.D., BauerJ.A., ChenX., SandersM.E., ChakravarthyA.B., ShyrY., et al. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest, 121, 2750–2767.
27.
LuX., LuX., WangZ.C., IglehartJ.D., ZhangX., and RichardsonA.L. (2008). Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat, 108, 191–201.
28.
MaX.J., SalungaR., TuggleJ.T., GaudetJ., EnrightE., McQuaryP., et al. (2003). Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A, 100, 5974–5979.
29.
MihalyZ., KormosM., LanczkyA., DankM., BudcziesJ., SzaszM.A., et al. (2013). A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer. Breast Cancer Res Treat, 140, 219–232.
30.
MooradianA.D., MorleyJ.E., and KorenmanS.G. (1987). Biological actions of androgens. Endocr Rev, 8, 1–28.
31.
NeveR.M., ChinK., FridlyandJ., YehJ., BaehnerF.L., FevrT., et al. (2006). A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell, 10, 515–527.
32.
Panet-RaymondV., GottliebB., BeitelL.K., PinskyL., and TrifiroM.A. (2000). Interactions between androgen and estrogen receptors and the effects on their transactivational properties. Mol Cell Endocrinol, 167, 139–150.
33.
ParkS., KooJ.S., KimM.S., ParkH.S., LeeJ.S., LeeJ.S., et al. (2011). Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann Oncol, 22, 1755–1762.
34.
PerouC.M., SorlieT., EisenM.B., van de RijnM., JeffreyS.S., ReesC.A., et al. (2000). Molecular portraits of human breast tumours. Nature, 406, 747–752.
35.
RechoumY., RovitoD., IacopettaD., BaroneI., AndoS., WeigelN.L., et al. (2014). AR collaborates with ERalpha in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat, 147, 473–485.
36.
RhodesD.R., Kalyana-SundaramS., MahavisnoV., VaramballyR., YuJ., BriggsB.B., et al. (2007). Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia, 9, 166–180.
37.
RhodesD.R., YuJ., ShankerK., DeshpandeN., VaramballyR., GhoshD., et al. (2004). ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia, 6, 1–6.
38.
RichardsonA.L., WangZ.C., De NicoloA., LuX., BrownM., MironA., et al. (2006). X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell, 9, 121–132.
39.
RingnerM., FredlundE., HakkinenJ., BorgA., and StaafJ. (2011). GOBO: gene expression-based outcome for breast cancer online. PLoS One, 6, e17911.
40.
RoyA.K., LavrovskyY., SongC.S., ChenS., JungM.H., VeluN.K., et al. (1999). Regulation of androgen action. Vitam Horm, 55, 309–352.
41.
SorlieT., PerouC.M., TibshiraniR., AasT., GeislerS., JohnsenH., et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A, 98, 10869–10874.
42.
ThakkarA., RajH., RavishankarMuthuvelan, B., BalakrishnanA., and PadigaruM. (2015). High expression of three-gene signature improves prediction of relapse-free survival in estrogen receptor-positive and node-positive breast tumors. Biomark Insights, 10, 103–112.
43.
TsangJ.Y., NiY.B., ChanS.K., ShaoM.M., LawB.K., TanP.H., et al. (2014). Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers. Ann Surg Oncol, 21, 2218–2228.
44.
Vera-BadilloF.E., TempletonA.J., de GouveiaP., Diaz-PadillaI., BedardP.L., Al-MubarakM., et al. (2014). Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst, 106, djt319.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
